专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3065829A4 COMPOSITIONS AND METHODS FOR TREATING MELANOMA 有权转让
标题翻译： ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON MELANOMEN
公开(公告)号：EP3065829A4
公开(公告)日：2017-07-05
申请号：EP14860949
申请日：2014-11-07
申请人： UNIV VIRGINIA PATENT FOUNDATION , SLINGLUFF JR CRAIG L , MAULDIN ILEANA S
发明人： SLINGLUFF JR CRAIG L , MAULDIN ILEANA S
IPC分类号： A61K9/00 , A61K31/352 , A61K31/353 , A61K31/7084 , A61K38/08 , A61K38/10 , A61K38/21 , A61P37/04
CPC分类号： A61K38/217 , A61K9/0014 , A61K9/0019 , A61K31/352 , A61K31/353 , A61K31/7084 , A61K38/08 , A61K38/10 , A61K45/06 , A61K47/12 , A61K2300/00

2. 发明公开

EP3065829A1 COMPOSITIONS AND METHODS FOR TREATING MELANOMA 有权转让
标题翻译： ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON MELANOMEN
公开(公告)号：EP3065829A1
公开(公告)日：2016-09-14
申请号：EP14860949.8
申请日：2014-11-07
申请人： University of Virginia Patent Foundation , Slingluff Jr., Craig L. , Mauldin, Ileana S.
发明人： SLINGLUFF, JR., Craig L. , MAULDIN, Ileana S.
IPC分类号： A61P37/04 , A61K38/21
CPC分类号： A61K38/217 , A61K9/0014 , A61K9/0019 , A61K31/352 , A61K31/353 , A61K31/7084 , A61K38/08 , A61K38/10 , A61K45/06 , A61K47/12 , A61K2300/00
摘要： Toll-like receptor (TLR) agonists can induce chemokine production. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFN to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells freshly isolated from surgical specimens also respond to TLR2/6 agonists +IFN by upregulating CXCL10 production, compared to treatment with either agent alone. It is also disclosed herein that these compounds are useful in inducing CLXL10 in other types of cancer. Collectively, these data identify a novel synergy of TLR2/6 agonists +IFN for inducing CXCL10 production directly from melanoma cells, raising the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.
摘要翻译： Toll样受体（TLR）激动剂可诱导趋化因子产生。我们发现TLR2和TLR6在人黑素瘤细胞中广泛表达，TLR2 / 6激动剂（MALP-2或FSL-1）与干扰素-γ（IFNγ）协同作用诱导黑素瘤细胞产生CXCL10。此外，与单独使用任一试剂的治疗相比，从外科手术标本新鲜分离的黑素瘤细胞和免疫细胞也通过上调CXCL10产生来响应TLR2 / 6激动剂+IFNγ。本文还公开了这些化合物可用于诱导其他类型的癌症中的CLXL10。总的来说，这些数据鉴定了TLR2 / 6激动剂+IFNγ的新协同作用，用于直接从黑素瘤细胞诱导CXCL10的产生，提高这些药物的肿瘤内给药可以改善黑素瘤中的免疫特征并且与其他免疫疗法组合具有价值的可能性，通过支持T细胞迁移到黑素瘤转移。

3. 发明申请

WO2012061738A1 DEVICE AND METHOD FOR SAFELY EXPANDING MINIMALLY INVASIVE SURGICAL INCISIONS 审中-公开
标题翻译：用于安全地扩展微创外科手术的设备和方法
公开(公告)号：WO2012061738A1
公开(公告)日：2012-05-10
申请号：PCT/US2011/059379
申请日：2011-11-04
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION , GUILFORD, William H. , SLINGLUFF, JR., Craig L. , JUDGE, Joshua M.
发明人： GUILFORD, William H. , SLINGLUFF, JR., Craig L. , JUDGE, Joshua M.
IPC分类号： A61B17/02
CPC分类号： A61B17/02 , A61B2017/320052
摘要： An insertion tongue of the retractor device may be pushed into the subject through the trocar incision, along one side of the organ. The tip of the insertion tongue pushes the impacted organ and its endoscopic recovery bag slightly away from the cavity wall. A scalpel is passed through the insertion guide with the tip of the scalpel blade in the retention guide on the back of the insertion tongue, and with the sharp side of the scalpel blade facing away from the organ and from the tongue of the retractor device. The scalpel is then passed down through the cavity wall, with its tip in the retention guide, while tension on the retractor device handle away from the organ, and gentle outward traction on the organ (and bag) permits removal of the organ (and bag) as soon as the opening is just large enough to allow it.
摘要翻译：牵开器装置的插入舌可以沿着器官的一侧通过套管切口被推入对象。插入舌头的尖端将冲击的器官及其内窥镜回收袋稍微远离腔壁。手术刀通过插入引导件，其中手术刀刀片的尖端在插入舌片背面的保持引导件中，并且解剖刀刀片的锋利侧面远离器官和从牵开器装置的舌部。然后手术刀通过腔壁向下传递，其顶端位于保持引导件中，而牵开器装置上的张力远离器官，并且器官（和袋）上的温和外向牵引可以移除器官（和袋））一开始只是足够大，以允许它。

4. 发明申请

WO2015070031A1 COMPOSITIONS AND METHODS FOR TREATING MELANOMA 审中-公开
标题翻译：组合物和治疗梅毒的方法
公开(公告)号：WO2015070031A1
公开(公告)日：2015-05-14
申请号：PCT/US2014/064578
申请日：2014-11-07
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION , SLINGLUFF, JR., Craig L. , MAULDIN, Ileana S.
发明人： SLINGLUFF, JR., Craig L. , MAULDIN, Ileana S.
IPC分类号： A61P37/04 , A61K38/21
CPC分类号： A61K38/217 , A61K9/0014 , A61K9/0019 , A61K31/352 , A61K31/353 , A61K31/7084 , A61K38/08 , A61K38/10 , A61K45/06 , A61K47/12 , A61K2300/00
摘要： Toll-like receptor (TLR) agonists can induce chemokine production. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFN to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells freshly isolated from surgical specimens also respond to TLR2/6 agonists +IFN by upregulating CXCL10 production, compared to treatment with either agent alone. It is also disclosed herein that these compounds are useful in inducing CLXL10 in other types of cancer. Collectively, these data identify a novel synergy of TLR2/6 agonists +IFN for inducing CXCL10 production directly from melanoma cells, raising the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.
摘要翻译： Toll样受体（TLR）激动剂可诱导趋化因子产生。我们发现TLR2和TLR6在人黑色素瘤细胞中广泛表达，TLR2 / 6激动剂（MALP-2或FSL-1）与干扰素-γ（IFN）协同作用，诱导黑素瘤细胞产生CXCL10，此外，黑素瘤细胞和与手术标本中新鲜分离的免疫细胞也可通过上调CXCL10产生而对TLR2 / 6激动剂+ IFN起反应，与单独使用任一试剂相比，本文还公开了这些化合物可用于诱导其他类型癌症中的CLXL10，这些数据鉴定了TLR2 / 6激动剂+ IFN的新协同作用，用于直接从黑素瘤细胞诱导CXCL10的产生，提高这些药物的肿瘤内给药可以改善黑素瘤中的免疫特征并且与其他免疫疗法组合有价值的可能性，通过支持T 细胞迁移到黑素瘤转移。

5. 发明申请

WO2013126402A1 COMPOSITION AND METHODS FOR TREATING MELANOMA 审中-公开
标题翻译：用于治疗梅毒的组合物和方法
公开(公告)号：WO2013126402A1
公开(公告)日：2013-08-29
申请号：PCT/US2013/026853
申请日：2013-02-20
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION , SLINGLUFF, JR., Craig, L. , ENGELHARD, Victor, H.
发明人： SLINGLUFF, JR., Craig, L. , ENGELHARD, Victor, H.
IPC分类号： A61K38/16 , A61K38/17 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/545 , A61K2039/55561 , A61K2039/572 , C07K16/2878
摘要： The present invention encompasses novel peptides useful for preventing and treating cancer, particularly melanoma. Multiple sequences of interest are provided and these sequences have been incorporated into other peptides to obtain a series of peptides of about 30 amino acid residues in length wherein the properties of each combine to yield an effective cocktail for treating melanoma, which surpasses the use of single peptides as immunogens, as well as shorter peptides as immunogens.
摘要翻译：本发明包括可用于预防和治疗癌症，特别是黑素瘤的新型肽。提供了多个感兴趣的序列，并且这些序列已经被并入其他肽中以获得长度为约30个氨基酸残基的一系列肽，其中每个肽的性质结合以产生用于治疗黑素瘤的有效混合物，其超过使用单一肽作为免疫原，以及较短的肽作为免疫原。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式